Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T; VADT Investigators.

Atherosclerosis. 2012 Oct;224(2):526-31. doi: 10.1016/j.atherosclerosis.2012.08.006. Epub 2012 Aug 21.

2.

High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators.

J Diabetes Complications. 2016 May-Jun;30(4):693-9. doi: 10.1016/j.jdiacomp.2016.01.012. Epub 2016 Jan 14.

PMID:
26861948
3.

Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

Diabetes. 2011 Feb;60(2):582-9. doi: 10.2337/db10-0915. Epub 2010 Oct 27.

4.

Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.

Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1213-1221. doi: 10.1161/ATVBAHA.117.309101. Epub 2017 May 4.

PMID:
28473443
5.

Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Hunt KJ, Baker N, Cleary P, Backlund JY, Lyons T, Jenkins A, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Atherosclerosis. 2013 Dec;231(2):315-22. doi: 10.1016/j.atherosclerosis.2013.09.027. Epub 2013 Oct 11.

6.

Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.

Vallejo J, Dunér P, Fredrikson GN, Nilsson J, Bengtsson E.

J Intern Med. 2017 Dec;282(6):496-507. doi: 10.1111/joim.12659. Epub 2017 Sep 25.

PMID:
28944562
7.

Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.

Lopes-Virella MF, Virella G.

J Atheroscler Thromb. 2013;20(10):743-54. Epub 2013 Aug 20. Review.

8.

Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.

Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY.

Clin Immunol. 1999 Feb;90(2):165-72.

PMID:
10080827
9.

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G; DCCT/EDIC Research Group.

Nephrol Dial Transplant. 2012 Apr;27(4):1416-23. doi: 10.1093/ndt/gfr454. Epub 2011 Aug 19.

10.

High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; DCCT/EDIC Study Group.

Diabetes Care. 2012 Jun;35(6):1333-40. doi: 10.2337/dc11-2040. Epub 2012 Apr 17.

11.

Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial.

Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ; VADT Study Group.

Atherosclerosis. 2013 Jun;228(2):502-7. doi: 10.1016/j.atherosclerosis.2013.03.024. Epub 2013 Apr 4.

PMID:
23608249
12.

Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G; DCCT/EDIC Research Group.

Atherosclerosis. 2011 Feb;214(2):462-7. doi: 10.1016/j.atherosclerosis.2010.11.012. Epub 2010 Nov 17.

13.

Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.

Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S.

J Lipid Res. 2011 Oct;52(10):1829-36. doi: 10.1194/jlr.M015776. Epub 2011 Aug 5.

14.

Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction.

Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK.

Circulation. 2000 Nov 21;102(21):2576-81.

15.

Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.

Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S.

J Am Coll Cardiol. 2012 Nov 20;60(21):2218-29. doi: 10.1016/j.jacc.2012.08.979. Epub 2012 Nov 1.

16.

The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.

Virella G, Lopes-Virella MF.

Front Endocrinol (Lausanne). 2012 Jun 15;3:76. doi: 10.3389/fendo.2012.00076. eCollection 2012.

17.

Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL.

J Am Coll Cardiol. 2003 Feb 5;41(3):360-70.

18.

Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.

Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF.

Clin Immunol Immunopathol. 1997 Oct;85(1):73-82.

PMID:
9325072
19.

Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.

Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators.

Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30.

PMID:
29382658
20.

Antibodies to oxidized lipoproteins and their relationship to myocardial infarction.

Ryan M, Owens D, Kilbride B, Collins P, Johnson A, Tomkin GH.

QJM. 1998 Jun;91(6):411-5.

PMID:
9709459

Supplemental Content

Support Center